鼠胶质瘤BCNU耐药细胞系的建立和特征  

Establishment and charcteristies of BCNU--resistant Murine glioma subline

作　　者：赵建农[1] 王伟民[1] 刘凤春[1] 索敬贤[1] 

机构地区：[1]白求恩医科大学第一临床学院神经外科

出　　处：《中风与神经疾病杂志》1993年第1期19-21,共3页Journal of Apoplexy and Nervous Diseases

摘　　要：本文通过对鼠胶质瘤G—422传代模型从半数抑制量0.5mg/kg BCNU(卡氮芥,Carmustine)开始诱导,经过七代传代,BCNU量增加100倍以上后,诱导组与对照组小鼠皮下瘤结节大小和荷瘤鼠寿命无显著差异,并且诱导组能稳定传代,保持对BCNU的耐受性,从而建成耐药细胞系。用非毒剂量利血平治疗后,耐药组肿瘤显著缩小,为进一步研究胶质瘤细胞耐药特性和治疗对策奠定了基础。Induction in vivo of G—422 murine glioma resistant to BCNU was studied by injecting BCNU from 0.5mg/kg to 60mg/kg. Acquisition of resistance to BCNU was present after seven transplant generations the character of resistance was stable. When resistant subline was treated with 250ug/kg reserpine the size of tumor decreased and the life span of glioma—bearing mice increased significantly. We concluded that reserpine had an effect on reversal resistance.

关 键 词：脑肿瘤 BCNU 药物耐受性 

分 类 号：R739.410.5[医药卫生—肿瘤]